Dr. Marc Gitzinger is Chief Executive Officer and co-founder of BioVersys with over 10 years of experience in the biotech industry, having launched a university spin-off in the field of antimicrobial resistance and growing it into a multi-asset clinical stage company. Some of these assets will address significant unmet medical needs in infectious conditions such as tuberculosis and hospital acquired Acinetobacter infections. Marc has raised over $70 mio in equity financing and secured over $30 mio in non-dilutive funding. He has also established several important partnerships with a Big Pharma and other development organizations. Multi-award-winning Biotech CEO, having received amongst others the Swiss Technology Award 2011, Venture Kick 2009 and Venture Leaders 2008 and 2017 awards for his work in founding and advancing BioVersys. Marc is also President of the Board of the BEAM Alliance, a European association representing over 70 European and international SMEs active in antimicrobial research and development and Board member of AMR Industry Alliance.
